UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Bone disease after renal transplantation

Authors
Thomas Nickolas, MD, MS
Sri G Yarlagadda, MD
L Darryl Quarles, MD
Kathryn Diemer, MD
Elizabeth Shane, MD
Section Editor
Daniel C Brennan, MD, FACP
Deputy Editor
Albert Q Lam, MD

INTRODUCTION

The major bone diseases that affect renal transplant recipients are osteoporosis and osteonecrosis (avascular necrosis), both of which cause significant long-term morbidity [1]. Osteoporosis increases the risk of fractures [1,2].

Because of their longstanding history of chronic kidney disease (CKD), renal transplant recipients are also vulnerable to persistent hyperparathyroidism and the mineral and bone disorders of chronic kidney disease (CKD-MBD). The evaluation and treatment of osteoporosis are made more complex because of CKD-MBD.

This topic reviews the monitoring, diagnosis, and treatment of osteoporosis and osteonecrosis among renal transplant recipients.

Persistent hyperparathyroidism and other disorders of mineral metabolism are discussed elsewhere. (See "Persistent hyperparathyroidism after renal transplantation".)

Other bone diseases that affect renal transplant patients, including dialysis-related amyloidosis and renal osteodystrophy associated with aluminum toxicity, are far less common and are discussed elsewhere. (See "Dialysis-related amyloidosis", section on 'Overview' and "Aluminum toxicity in chronic kidney disease".)

                       

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2017. | This topic last updated: Jun 23, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Bouquegneau A, Salam S, Delanaye P, et al. Bone Disease after Kidney Transplantation. Clin J Am Soc Nephrol 2016; 11:1282.
  2. Mikuls TR, Julian BA, Bartolucci A, Saag KG. Bone mineral density changes within six months of renal transplantation. Transplantation 2003; 75:49.
  3. Rajapakse CS, Leonard MB, Bhagat YA, et al. Micro-MR imaging-based computational biomechanics demonstrates reduction in cortical and trabecular bone strength after renal transplantation. Radiology 2012; 262:912.
  4. Pichette V, Bonnardeaux A, Prudhomme L, et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996; 28:105.
  5. Marcén R, Caballero C, Pascual J, et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation 2006; 81:826.
  6. Naylor KL, Garg AX, Hodsman AB, et al. Long-term changes in bone mineral density in kidney transplant recipients. Transplantation 2014; 98:1279.
  7. Brandenburg VM, Politt D, Ketteler M, et al. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 2004; 77:1566.
  8. Brandenburg VM, Ketteler M, Fassbender WJ, et al. Development of lumbar bone mineral density in the late course after kidney transplantation. Am J Kidney Dis 2002; 40:1066.
  9. Cruz DN, Wysolmerski JJ, Brickel HM, et al. Parameters of high bone-turnover predict bone loss in renal transplant patients: a longitudinal study. Transplantation 2001; 72:83.
  10. Casez JP, Lippuner K, Horber FF, et al. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002; 17:1318.
  11. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325:544.
  12. Almond MK, Kwan JT, Evans K, Cunningham J. Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 1994; 66:52.
  13. Iyer SP, Nikkel LE, Nishiyama KK, et al. Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton. J Am Soc Nephrol 2014; 25:1331.
  14. Nishiyama KK, Pauchard Y, Nikkel LE, et al. Longitudinal HR-pQCT and image registration detects endocortical bone loss in kidney transplantation patients. J Bone Miner Res 2015; 30:554.
  15. Zisman AL, Sprague SM. Bone disease after kidney transplantation. Adv Chronic Kidney Dis 2006; 13:35.
  16. Nisbeth U, Lindh E, Ljunghall S, et al. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999; 67:1218.
  17. Nikkel LE, Hollenbeak CS, Fox EJ, et al. Risk of fractures after renal transplantation in the United States. Transplantation 2009; 87:1846.
  18. Horber FF, Casez JP, Steiger U, et al. Changes in bone mass early after kidney transplantation. J Bone Miner Res 1994; 9:1.
  19. Ulivieri FM, Piodi LP, Aroldi A, Cesana BM. Effect of kidney transplantation on bone mass and body composition in males. Transplantation 2002; 73:612.
  20. Evenepoel P, Behets GJ, Viaene L, D'Haese PC. Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. Kidney Int 2017; 91:469.
  21. Cunningham J. Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. J Am Soc Nephrol 2007; 18:223.
  22. Perrin P, Caillard S, Javier RM, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant 2013; 13:2653.
  23. Yakupoglu HY, Corsenca A, Wahl P, et al. Posttransplant acidosis and associated disorders of mineral metabolism in patients with a renal graft. Transplantation 2007; 84:1151.
  24. Evenepoel P, Cooper K, Holdaas H, et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 2014; 14:2545.
  25. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.8. Bone disease. Nephrol Dial Transplant 2002; 17 Suppl 4:43.
  26. Lenihan CR, Sukumaran Nair S, Vangala C, et al. Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients. Am J Kidney Dis 2017; 69:595.
  27. Monier-Faugere MC, Mawad H, Qi Q, et al. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000; 11:1093.
  28. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112:352.
  29. Movsowitz C, Epstein S, Fallon M, et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123:2571.
  30. Cayco AV, Wysolmerski J, Simpson C, et al. Posttransplant bone disease: evidence for a high bone resorption state. Transplantation 2000; 70:1722.
  31. Cueto-Manzano AM, Konel S, Crowley V, et al. Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation 2003; 75:2053.
  32. Cunningham J. Posttransplantation bone disease. Transplantation 2005; 79:629.
  33. Goffin E, Devogelaer JP, Lalaoui A, et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002; 15:73.
  34. Monegal A, Navasa M, Guañabens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68:83.
  35. Luo L, Shi Y, Bai Y, et al. Impact of tacrolimus on bone metabolism after kidney transplantation. Int Immunopharmacol 2012; 13:69.
  36. Perrin P, Kiener C, Javier RM, et al. Recent changes in chronic kidney disease-mineral and bone disorders (CKD-MBD) and associated fractures after kidney transplantation. Transplantation 2016.
  37. Nikkel LE, Mohan S, Zhang A, et al. Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am J Transplant 2012; 12:649.
  38. Mainra R, Elder GJ. Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation. Clin J Am Soc Nephrol 2010; 5:117.
  39. Nickolas TL, Stein EM, Dworakowski E, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 2013; 28:1811.
  40. Akaberi S, Simonsen O, Lindergård B, Nyberg G. Can DXA predict fractures in renal transplant patients? Am J Transplant 2008; 8:2647.
  41. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva 1994. http://whqlibdoc.who.int/trs/WHO_TRS_843.pdf (Accessed on March 09, 2012).
  42. Heaf JG. Bone disease after renal transplantation. Transplantation 2003; 75:315.
  43. Wissing KM, Broeders N, Moreno-Reyes R, et al. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005; 79:108.
  44. Ponticelli C, Sala G. Vitamin D: a new player in kidney transplantation? Expert Rev Clin Immunol 2014; 10:1375.
  45. De Sévaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 2002; 13:1608.
  46. Torres A, García S, Gómez A, et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004; 65:705.
  47. El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 2003; 14:2975.
  48. Smerud KT, Dolgos S, Olsen IC, et al. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. Am J Transplant 2012; 12:3316.
  49. Josephson MA, Schumm LP, Chiu MY, et al. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 2004; 78:1233.
  50. Nam JH, Moon JI, Chung SS, et al. Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc 2000; 32:1876.
  51. Amer H, Griffin MD, Stegall MD, et al. Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant 2013; 13:1576.
  52. Fan SL, Almond MK, Ball E, et al. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000; 57:684.
  53. Grotz WH, Rump LC, Niessen A, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998; 66:1004.
  54. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12:1530.
  55. Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003; 63:1130.
  56. Fan SL, Kumar S, Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int 2003; 63:2275.
  57. Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004; 43:566.
  58. Cruz DN, Brickel HM, Wysolmerski JJ, et al. Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant 2002; 2:62.
  59. Mitterbauer C, Schwarz C, Haas M, Oberbauer R. Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006; 21:2275.
  60. Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005; 45:638.
  61. El-Agroudy AE, El-Husseini AA, El-Sayed M, et al. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 2005; 67:2039.
  62. Kan SL, Ning GZ, Chen LX, et al. Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis. Medicine (Baltimore) 2016; 95:e2679.
  63. Versele EB, Van Laecke S, Dhondt AW, et al. Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials. Transpl Int 2016; 29:153.
  64. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007; :CD005015.
  65. Wilson LM, Rebholz CM, Jirru E, et al. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2017; 166:649.
  66. Toth-Manikowski SM, Francis JM, Gautam A, Gordon CE. Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis. Clin Transplant 2016; 30:1090.
  67. Weber TJ, Quarles LD. Preventing bone loss after renal transplantation with bisphosphonates: we can... but should we? Kidney Int 2000; 57:735.
  68. Bonani M, Frey D, Brockmann J, et al. Effect of Twice-Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial. Am J Transplant 2016; 16:1882.
  69. Bonani M, Meyer U, Frey D, et al. Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients. Kidney Blood Press Res 2016; 41:614.
  70. Cejka D, Benesch T, Krestan C, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008; 8:1864.
  71. Babayev R, Nickolas TL. Bone Disorders in Chronic Kidney Disease: An Update in Diagnosis and Management. Semin Dial 2015; 28:645.
  72. Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13:2294.
  73. Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis 2016; 67:559.
  74. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.
  75. Polyzos SA, Terpos E. Clinical vertebral fractures following denosumab discontinuation. Endocrine 2016; 54:271.
  76. Lamy O, Gonzalez-Rodriguez E, Stoll D, et al. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report. J Clin Endocrinol Metab 2017; 102:354.
  77. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028.
  78. Nehme D, Rondeau E, Paillard F, et al. Aseptic necrosis of bone following renal transplantation: relation with hyperparathyroidism. Nephrol Dial Transplant 1989; 4:123.
  79. Ibels LS, Alfrey AC, Huffer WE, Weil R 3rd. Aseptic necrosis of bone following renal transplantation: experience in 194 transplant recipients and review of the literature. Medicine (Baltimore) 1978; 57:25.
  80. Metselaar HJ, van Steenberge EJ, Bijnen AB, et al. Incidence of osteonecrosis after renal transplantation. Acta Orthop Scand 1985; 56:413.
  81. Parfrey PS, Farge D, Parfrey NA, et al. The decreased incidence of aseptic necrosis in renal transplant recipients--a case control study. Transplantation 1986; 41:182.
  82. Abbott KC, Oglesby RJ, Agodoa LY. Hospitalized avascular necrosis after renal transplantation in the United States. Kidney Int 2002; 62:2250.
  83. Abbott KC, Koff J, Bohen EM, et al. Maintenance immunosuppression use and the associated risk of avascular necrosis after kidney transplantation in the United States. Transplantation 2005; 79:330.
  84. Tang S, Chan TM, Lui SL, et al. Risk factors for avascular bone necrosis after renal transplantation. Transplant Proc 2000; 32:1873.
  85. Goffin E, Vande Berg B, Devogelaer JP, et al. Post-renal transplant syndrome of transient lower limb joint pain: description under a tacrolimus-based immunosuppression. Clin Nephrol 2003; 59:98.
  86. Gauthier VJ, Barbosa LM. Bone pain in transplant recipients responsive to calcium channel blockers. Ann Intern Med 1994; 121:863.
  87. Goffin E. Transient bone marrow edema in renal transplantation: a distinct post-transplantation syndrome with a characteristic MRI appearance. Am J Transplant 2003; 3:96.
  88. Coates PT, Tie M, Russ GR, Mathew TH. Transient bone marrow edema in renal transplantation: a distinct post-transplantation syndrome with a characteristic MRI appearance. Am J Transplant 2002; 2:467.